The Developmental Funds are used to promote strategic cancer-research initiatives that the Cancer Center Director and other senior Cancer Center members have deemed important for the overall success of Cold Spring Harbor Laboratory's cancer research program. An important use of these funds has been to support new faculty recruited to the Cancer Center and to promote development of new technologies, either within the research programs or in the Cancer Center Shared Resources. CSHL has a dynamic research environment with a relatively high turnover of faculty, compared to the traditional university model. This provides an opportunity to recruit outstanding young scientists at the beginning of their careers. The Developmental Funds are a critical component for this recruitment and have provided support for investigators who have gone on to establish vibrant and productive cancer-research programs. These investigators have been successful in obtaining independent funding to continue their research. An extremely valuable source of funding, the Developmental funds give the Cancer Center Director the flexibility to support novel projects and incorporate new technologies and approaches. This also significantly enhances the opportunity for investigators to pioneer new and exciting research directions. The Developmental Funds strengthen the Cancer Center initiatives by allowing the recruitment of additional new faculty, whose inventive research approaches complement and expand upon current cancer-research programs.

Public Health Relevance

Developmental funds at the Cold Spring Harbor Laboratory are used primarily for recruitment of new faculty whose research can expand existing cancer research programs and move into new directions to promote the Cancer Center's mission to understand the underlying mechanisms of cancer as a means to developing strategies for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA045508-26
Application #
8473665
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
26
Fiscal Year
2013
Total Cost
$617,703
Indirect Cost
$127,991
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Krishnan, Navasona; Bonham, Christopher A; Rus, Ioana A et al. (2018) Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development. Nat Commun 9:283
Pommier, Arnaud; Anaparthy, Naishitha; Memos, Nicoletta et al. (2018) Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science 360:
Krishnan, Navasona; Felice, Christy; Rivera, Keith et al. (2018) DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease. Genes Dev 32:944-952
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480
Nattestad, Maria; Goodwin, Sara; Ng, Karen et al. (2018) Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. Genome Res 28:1126-1135
Connell, Claire M; Raby, Sophie E M; Beh, Ian et al. (2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist 23:116-117
Wong, Mandy S; Kinney, Justin B; Krainer, Adrian R (2018) Quantitative Activity Profile and Context Dependence of All Human 5' Splice Sites. Mol Cell 71:1012-1026.e3
Snider, Justin M; Snider, Ashley J; Obeid, Lina M et al. (2018) Probing de novo sphingolipid metabolism in mammalian cells utilizing mass spectrometry. J Lipid Res 59:1046-1057
Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel et al. (2018) Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23:62-70
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8

Showing the most recent 10 out of 380 publications